A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-994 in Healthy Participants

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

121 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-05-01

Study Completion Date

2020-03-29

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to assess the safety and tolerability of TAK-994 following single and multiple oral doses in healthy non-Japanese and Japanese adult participants and healthy elderly participants.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of TAK-988 in Healthy Participants

NCT04082481

Healthy Volunteers

WITHDRAWN PHASE1

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single Ascending Dose and Multiple Doses With Titration of TAK-935 in Healthy Japanese Participants

NCT04461483

Healthy Volunteer

COMPLETED PHASE1

A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Ascending Oral Single Dose of TAK-418 in Healthy Participants

NCT03228433

Healthy Participants

COMPLETED PHASE1

Phase 1 TAK-906 Single and Multiple Ascending Dose Study in Japanese Healthy Male Participants

NCT03237156

Japanese Healthy Adult Male Participants

COMPLETED PHASE1

Phase 1 Study of TAK-831 in Healthy Adult Asian Subjects

NCT03687684

Healthy Volunteers

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The drug being tested in this study is called TAK-994. TAK-994 is being tested to find a safe and well-tolerated dose in healthy participants (non-Japanese and Japanese) and healthy elderly participants. The study will enroll up to approximately 160 healthy participants. The study consists of 6 parts and up to 20 cohorts as mentioned below.

* TAK-994: Part A: Single-rising dose (SRD) design to assess the safety, tolerability, and PK of TAK-994 and effect of food on the PK of the TAK-994
* TAK-994: Part B: MRD design to assess the safety, tolerability, PK and PD of TAK-994
* TAK-994: Part C: MRD design to assess the safety, tolerability, PK and PD of TAK-994 and also central nervous system penetration relative to plasma concentrations of TAK-994
* TAK-994: Part D: MRD design to assess the safety, tolerability, PK and PD of TAK-994 for HE participants
* TAK-994: Part E: SRD and MRD design to assess the safety, tolerability, PK and PD of TAK-994 for Japanese origin participants
* TAK-994: Part F (Optional Cohort): Nonrandomized design to assess orexin (OX) levels in the cerebrospinal fluid (CSF) of untreated healthy adult participants.

Participants in each cohort will be randomized to receive treatment with TAK-994 or matching placebo which will remain undisclosed to the participant and study doctor during the study (unless there is an urgent medical need). Participants in optional Part F will receive no study drug.

This multi-center trial will be conducted in the United States. The overall duration of the study is approximately 10 months. Participants will be followed up for 7 days after the last dose of study drug for a follow-up assessment.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy Participants

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SEQUENTIAL

Primary Study Purpose

OTHER

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

TAK-994: Part A

TAK-994 tablet or matching placebo, orally, once on Day 1 to healthy non-Japanese participants. Sentinel dosing will be done in the first 2 cohorts of Part A (Cohorts A1 and A2 \[fasted and fed dosing conditions\]). Dose escalation in Cohorts A2 to A6 will be based on emerging safety, tolerability, and PK (pharmacokinetic) data from previous cohorts.

Group Type EXPERIMENTAL

TAK-994

Intervention Type DRUG

TAK-994 tablets.

TAK-994 Placebo

Intervention Type DRUG

TAK-994 placebo-matching tablets.

TAK-994: Part B

TAK-994 tablet or matching placebo, orally, once daily or twice daily from Day 1 to Day 14 to healthy non-Japanese participants. Dose escalation will be based on review of the emerging safety, PK, and PD (pharmacodynamic) data from Part A. Fixed-dose titration regimens may also be evaluated based on review of the emerging safety, PK, and tolerability data from previous cohorts.

Group Type EXPERIMENTAL

TAK-994

Intervention Type DRUG

TAK-994 tablets.

TAK-994 Placebo

Intervention Type DRUG

TAK-994 placebo-matching tablets.

TAK-994: Part C

TAK-994 tablet or matching placebo, orally, once daily or twice daily from Day 1 to Day 7 to healthy non-Japanese participants. Dose will be determined based on previous multiple-rising dose (MRD) cohorts.

Group Type EXPERIMENTAL

TAK-994

Intervention Type DRUG

TAK-994 tablets.

TAK-994 Placebo

Intervention Type DRUG

TAK-994 placebo-matching tablets.

TAK-994: Part D

TAK-994 tablet or matching placebo, orally, once daily or twice daily from Day 1 to Day 14 to healthy non-Japanese elderly participants. Dose will be determined based on previous MRD cohorts. Fixed-dose titration regimens may also be evaluated based on review of the emerging safety, PK, and tolerability data from previous cohorts.

Group Type EXPERIMENTAL

TAK-994

Intervention Type DRUG

TAK-994 tablets.

TAK-994 Placebo

Intervention Type DRUG

TAK-994 placebo-matching tablets.

TAK-994: Part E

TAK-994 tablet or matching placebo, orally, once or twice on Day 1, followed by a washout period of 2 days and on Day 4 and continue to Day 17 to healthy Japanese participants. Dose will be determined based on previous MRD cohorts. Fixed-dose titration regimens may also be evaluated based on review of the emerging safety, PK, and tolerability data from previous cohorts.

Group Type EXPERIMENTAL

TAK-994

Intervention Type DRUG

TAK-994 tablets.

TAK-994 Placebo

Intervention Type DRUG

TAK-994 placebo-matching tablets.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

TAK-994

TAK-994 tablets.

Intervention Type DRUG

TAK-994 Placebo

TAK-994 placebo-matching tablets.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Be normotensive, with no history of hypertension or use of antihypertensive medication. Blood pressure (BP) must be less than (\<) 140 millimeter of mercury (mmHg) (systolic) and \<90 mmHg (diastolic).

Healthy Adult and Elderly Participants (Parts A through D and Part F)
2. Must have a body mass index (BMI) greater than or equal to (\>=) 18.0 and less than or equal to (\<=) 30.0 kilogram per square meter (kg/m\^2) at the screening visit (non-Japanese only).

Healthy Adult Participants (Parts A, B, C, and F)
3. Must be aged 18 to 55 years, inclusive, at the screening visit.
4. Must have a body weight \>=50 kilogram (kg) at the screening visit.

HE Participants (Part D)
5. Must be aged \>=65 years, inclusive, at the time of informed consent.
6. Must have a body weight \>=40 kg at the screening visit.

Healthy Japanese Adult Participants (Part E)
7. Must be aged 18 to 55 years, inclusive, at the screening visit.
8. Must have a BMI \>=18.0 and \<=26.0 kg/m\^2 at the screening visit.
9. Must have been born in Japan to a Japanese mother and father and have maternal and paternal Japanese grandparents.
10. Must have not been away from Japan for more than 10 years at the screening visit.
11. In the opinion of the investigator, must have a lifestyle that has not changed significantly since relocation from Japan.

Exclusion Criteria

1. Has a known hypersensitivity to any component of the formulation of TAK-994 or related compounds.
2. Has a risk of suicide according to endorsement of Item 4 or 5 of the screening/baseline visit Columbia Suicide Severity Rating Scale (C-SSRS) or has made a suicide attempt in the previous 6 months.
3. Has a lifetime history of major psychiatric disorder, such as bipolar disorder or schizophrenia. Participant who have history of major depressive disorder (MDD) may be included, but participants who have current active MDD or who have had active MDD in the past 6 months are excluded.
4. Has a clinically significant history of head injury or head trauma.
5. Has a history of cerebral ischemia, transient ischemic attack, intracranial aneurysm, or arteriovenous malformation.
6. Screening electrocardiogram (ECG) reveals a QT interval with the Fridericia's correction method (QTcF) greater than (\>) 450 millisecond (ms) (men) or \>470 ms (women).
7. Has a resting heart rate outside of the range of 45 to 100 beats per minute, confirmed on repeat testing within a maximum of 30 minutes).

Healthy Non-Japanese Adult Participants (Part C and Part F)
8. Has undergone CSF collection within 30 days before check-in (Day -2 \[Part C\] or Day -1 \[Part F\]).
9. Has a known hypersensitivity to anesthesia or its derivatives used during CSF collection or to any medication used to prepare the area of lumbar puncture.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes